BT
BLONDER TONGUE LABORATORIES INC (BDRL)·Q4 2021 Earnings Summary
Executive Summary
- Q4 2021 net sales were $3.993M, down 7.7% YoY; gross profit was $1.369M; net loss was $(0.927)M with diluted EPS of $(0.07) .
- Product mix shifted positively: video encoder/transcoder sales rose to $2.529M (vs. $1.381M YoY) and NXG series to $0.614M (vs. $0.135M YoY), partially offsetting declines in legacy CPE, DOCSIS, analog modulation, and coax distribution .
- Management cited severe semiconductor supply-chain disruptions driving price increases and margin compression in Q4; year-end backlog reached ~$10.240M, providing 2022 sales visibility amid uncertainty .
- Liquidity remains tight; MidCap facility availability was ~$92K at year-end and the 2021 10-K carries a going-concern explanatory paragraph, a key overhang and potential stock-reaction catalyst .
What Went Well and What Went Wrong
What Went Well
- Encoder/transcoder and NXG momentum: “Sales of video encoder/transcoder products were $2,529,000… and our NXG series products were $614,000… in the fourth quarter of 2021” .
- Strategic partnerships and certifications: DIRECTV certification for Clearview 4:2 transcoder family and TiVo-specific NXG configuration broaden market access and dealer subsidies .
- Full-year profitability aided by product mix and non-operating income: “Positive net income of $84,000… improved blended product gross margin… and recognition of significant nonoperating income… ERTC and PPP loan forgiveness” .
What Went Wrong
- Supply chain and margin pressure: “Global semiconductor… bottlenecks… negative impact on our fourth quarter… Q4 margins took quite a hit… price increases to compensate for raw material premiums” .
- Legacy portfolio drag: Sharp declines in CPE ($0.023M), DOCSIS ($0.122M), analog modulation ($0.133M), and coax distribution ($0.171M) in Q4; management expects analog/coax declines to continue in 2022 .
- Liquidity/going concern risk: Only ~$92K borrowing availability under MidCap at 12/31/21; auditor included an “Explanatory Paragraph-Going Concern” in the 2021 10-K .
Financial Results
Quarterly performance vs prior quarters
Q4 2021 vs Q4 2020
Segment/Product mix – Q4
KPIs and Balance Sheet Snapshot
Guidance Changes
Earnings Call Themes & Trends
Management Commentary
- “Although the Company was able to realize positive net earnings for the full year of 2021, the global semiconductor supply chain bottlenecks… had a significant negative impact on our fourth quarter.” (CEO Ted Grauch) .
- “Our improved product mix yielded a blended product gross margin improvement in 2021 of 39.8% versus 30% in 2020.” (CEO) .
- “Our 2021 fourth quarter sales decreased by 7.7% to $3.993 million… net loss… $927,000… we had to engage in a series of price increases.” (CEO) .
- “The Company had approximately $92,000… available for borrowing under the MidCap Facility… 10-K includes an Explanatory Paragraph-Going Concern.” (CFO) .
- “DIRECTV… certification by DIRECTV for our Clearview 4:2 IP video transcoder product line… qualified for DIRECTV’s equipment subsidy program.” (CEO) .
Q&A Highlights
- Supply chain granularity: Issues shifted from high-end SoCs to “smaller parts… crystals… power conditioning… PCBs” with ad hoc redesigns and alternate sourcing to keep lines running .
- Backlog composition: Partly structural due to 6‑month rolling forecast POs; significant portion constrained by parts shortages; timing of recovery uncertain .
- Pricing strategy: Broad price hikes accepted by customers; intent to roll back when costs normalize; some vendors already pulled back from “2x” peak to ~10–15% above pre-pandemic pricing .
- Margin commentary: Q4 margins “took quite a hit”; pricing aids recovery but volatility persists (e.g., Shenzhen airport closures delaying parts) .
- New products ramp: DIRECTV-certified Clearview already shipping and included in backlog; new Clearview encoder expected to ship ~10–14 weeks after press release .
Estimates Context
- Wall Street consensus (S&P Global) could not be retrieved during this session for Q4 2021 EPS and revenue; therefore estimate comparisons are unavailable at this time. If consensus exists, we expect near-term revisions to reflect the product-mix strength offset by supply-chain constraints and margin pressure [S&P Global consensus unavailable].
Key Takeaways for Investors
- Mix upgrade is real: Encoder/transcoder and NXG lines now dominate sales, structurally improving gross margin potential; watch for supply normalization to unlock backlog conversion .
- Liquidity/going concern is the primary risk overhang: Very limited revolver capacity and auditor’s going-concern paragraph constrain risk appetite until profitability and capital access improve .
- Near-term trading setup: Headline catalysts include DIRECTV/TiVo channel validation and backlog visibility; but supply-chain headlines and any financing actions may drive volatility .
- Margin trajectory hinges on input costs and batch efficiency; price actions provide an offset but labor inefficiencies from smaller runs weighed in Q4 .
- 2022 outlook: Management expects higher sales vs 2021 on backlog, with legacy product declines continuing and high-tech lines stable/up, conditional on semiconductor supply .
- Full-year profitability in 2021 was aided by ERTC and PPP forgiveness; core operating profitability still needs to be proven as supply-chain disruptions abate .
- Monitoring list: backlog conversion pace, vendor delivery confirmations into late 2022, hospitality demand recovery for DOCSIS line, and any capital raise or covenant updates .